In numerous preclinical studies, anti-CD19 CAR T-cells demonstrated selective lysis of B-lineage tumor lines and primary leukemia/lymphoma cells in vitro and also showed potent antitumor activity in murine xenograft and immunocompetent mouse models[152, 155–164]. The gene discussed is CD19; the disease is neoplasm.